A randomized phase II trial of low dose aspirin versus placebo in high risk individuals with CT screen detected lung nodules (MDA2013-01-01)
Ended Awarded Last action
- Contract number
- HHSN26100002
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $999,843
Award facts
- Opportunity
-
- TORFPA Solicitation number
- Contract value 100% obligated
- $999,843.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Houston, TX 77230, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$13,854 | |
| Funding Only Action | -$94,563 | |
| Change Order | $13,854 | |
| Original award | $1,094,406 |
About this award
The National Cancer Institute issued a delivery order to The University of Texas M.D. Anderson Cancer Center on September 20, 2013, with a ceiling value of $999,843.18 under the Cancer Prevention Agent Development Program 2012-2017 IDIQ for a randomized Phase II trial of low-dose aspirin versus placebo in high-risk individuals with CT screen-detected lung nodules.
The Cancer Prevention Agent Development Program is an NCI indefinite delivery contract supporting early-phase clinical research in cancer prevention. Place of performance is Houston, TX. The order was priced as cost no fee with an ultimate completion date of September 19, 2018. No set-aside was applied to this order.
Quick answers
Who was awarded contract HHSN26100002?
HHSN26100002 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 20, 2013.
How much is contract HHSN26100002 worth?
The government has obligated $999,843 on HHSN26100002.
Is contract HHSN26100002 an order under another contract?
Yes. HHSN26100002 is a delivery order under HHSN261201200034I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100002 competed?
The extent of competition for HHSN26100002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award